Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

Obinutuzumab is a type 2, glycoengineered, anti-CD20 antibody recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL). In this nonrandomized, parallel-cohort, phase 1b, multicenter study, we explored the safety and preliminary efficacy of obinutuzumab-bendam...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Brown, Jennifer R., O’Brien, Susan, Kingsley, C. Daniel, Eradat, Herbert, Pagel, John M., Lymp, James, Hirata, Jamie, Kipps, Thomas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2015
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416529/
https://ncbi.nlm.nih.gov/pubmed/25769620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-12-613570
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky